Biocon Sdn News Today

/PRNewswire/ -- The Insight Partners published latest research study on "Insulin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type [Long...

Biocon Biologics has created a Center of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to manufacture a broad portfolio of regular, basal and rapid insulins.

MBR has recognised the company’s 562,000 sq. ft. facility as the first and largest integrated insulin manufacturer in Malaysia.

This is Mylan's third voluntary recall of insulin glargine this year, caused by the potential for the labels to be missing on some prefilled pens.

On July 5, Mylan announced another voluntary recall of a batch of Insulin Glargine (insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens “due to the potential for...

CANONSBURG (dpa-AFX) - Mylan Pharmaceuticals Inc., affiliated to healthcare company Viatris Inc., is recalling certain Insulin Glargine (Insulin glargine-yfgn) Injection prefilled pens due to the

The rh-Insulin formulations, Insugen-R, Insugen-N and lnsugen-30/70, are manufactured at Biocon Sdn. Bhd.s Johor facility.

Malaysias Ministry of Health has awarded a three-year contract to Biocon Sdn Bhd. As part of the deal, the Biocon subsidiary will manufacture and supply its range of insulins to its partner Duopharma Marketing Sdn Bhd (DMktg)

Biocon Biologics’ Insugen awarded a 3-year contract by Ministry of Health, Malaysia

Mylan is voluntarily recalling 1 lot of Semglee (insulin glargine) prefilled pens.